Sign In
to Vote &
Create Storyboards.
 
Checkpoint inhibitor therapies have made metastatic melanoma and other cancers a survivable condition for 20 to 30 percent of treated patients, but clinicians have had very limited ways of knowing which patients will respond. Researchers have uncovered a novel mechanism by which tumors suppress the immune system. Their findings also usher in the possibility that a straightforward blood test could predict and monitor cancer patients' response to immunotherapy.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard